Hyperfine Inc (HYPR) Stock Analysis

Verdict: WATCH (do not buy)

Hyperfine is a binary bet on clinical adoption of portable MRI; the model sees a race between triple-digit revenue growth and a 14-month cash runway.

Investment score: 48/100

Analysis as of

Is Hyperfine Inc stock worth reviewing? The TradeMates thesis

Hyperfine offers a high-risk, high-reward entry into portable diagnostics. While technology adoption is growing (30% revenue growth), the -226% net margin necessitates constant monitoring of the cash runway.

7-factor investment score

Hyperfine Inc opportunities and risks

What speaks for HYPR

What speaks against HYPR

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
HYPRn/a8.0xn/a51.2%-226.9%-23.3%
INGNn/a0.5xn/a48.7%-7.1%-5.6%
APYXn/a3.1xn/a32.3%-16.4%-5.2%
KRMDn/a4.4xn/a61.5%-5.3%0.1%
OWLTn/a0.9xn/a50.9%-43.0%-11.0%
STXSn/a5.1xn/a53.9%-69.5%-9.7%
Peer mediann/a3.1xn/a50.9%-16.4%-5.6%

Frequently asked questions about Hyperfine Inc (HYPR)

Is HYPR stock a good investment?

The TradeMates model rates Hyperfine Inc as WATCH (do not buy) with an investment score of 48/100. Hyperfine offers a high-risk, high-reward entry into portable diagnostics. While technology adoption is growing (30% revenue growth), the -226% net margin necessitates constant monitoring of the cash runway. This is algorithmic model output, not personal investment advice.

Is HYPR stock a buy?

The TradeMates model verdict for HYPR is WATCH (do not buy) with an investment score of 48/100. Treat this as a model signal to review, not a personal buy recommendation.